Skip to content

The archive

Dark Peptides

The compounds that disappeared, failed, stalled or never made it out of development. Their stories are the most useful education in this registry — because most of them are still being sold, and still being talked about as if none of it happened.

Three things people confuse when they say a peptide is 'available'

Current clinical development

An active trial programme under regulatory oversight. Not approved yet — but evidence is still being generated, and the scientific question is still open.

Regulatory availability

Approved medicines reach patients through licensed prescribers and pharmacies, for defined indications. Approval is indication-specific — never a general endorsement of every use being discussed online.

The unregulated market

A molecule can appear on research-chemical websites long after its development programme died — or without one ever existing. That kind of availability is a supply-chain fact, not an evidence signal. We never link to suppliers.

Discontinued does not mean dangerous

Development stops for many reasons: trials missing their endpoints, commercial decisions, better competitors, strategic pivots — and sometimes safety findings. "Discontinued" is a statement about a programme, not proof a molecule is poison. The reverse matters just as much: continued availability on the internet is not evidence of safety, efficacy or quality.

Zombie peptides: dead programmes, living hype

A "zombie peptide" is a compound still discussed online as cutting-edge even though the original clinical programme was abandoned. The molecule does not know the programme died — and the marketing never got the memo. Treat "everyone is talking about it" as a cultural signal, not an evidence signal.

Browse the archive

Filter by how the programme ended and how strong the underlying evidence ever was.

Lifecycle status

Why development stopped

Evidence level

2 of 2 archived compounds

Ipamorelin

Discontinued — efficacyL2Preclinical

A selective growth hormone secretagogue discontinued after its trials missed their endpoints — now sold for physique and recovery claims no trial ever tested.

Furthest stage not established

Stopped: Did not meet endpoints

CJC-1295

DiscontinuedL3Early human

A long-acting GHRH analogue abandoned after early human studies — it reliably raises growth hormone, but the outcomes it is sold for were never tested.

Furthest established stage: Phase I

Stopped: Reason not established

Looking for compounds that did make it? Browse the full A–Z registry.